The effects of oral contraceptives including low-dose estrogen and drospirenone on the concentration of leptin and ghrelin in polycystic ovary syndrome

Fertility and Sterility

Volumn 92, Issue 2, 2009, Pages 660-666

  Saǧsöz, Nevin ^a   Orbak, Zerrin ^b   Noyan, Volkan ^a   Yücel, Aykan ^a   Uçar, Banu ^c   Yildiz, Leyla ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

^c Department of Obstetrics and Gynecology   (Turkey)

Author keywords

drospirenone; ghrelin; leptin; oral contraceptive; PCOS

Indexed keywords

ANDROSTENEDIONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; FOLLITROPIN; GHRELIN; LEPTIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WAIST HIP RATIO;

ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FEMALE; GHRELIN; HUMANS; LEPTIN; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME;

EID: 67651085354     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.07.008     Document Type: Article

References (54)

1. Anovulation and the polycystic ovary. In: Speroff L., and Fritz M.A. (Eds). Clinical Gynecologic Endocrinology and Infertility (2005), Lippincott Williams & Wilkins, Philadelphia 465-498
2. Hull M.G. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1 (1987) 235-245
3. Norman R.J., Masters L., Milner C.R., Wang J.X., and Davies M.J. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16 (2001) 1995-1998
4. Obesity. In: Speroff L., and Fritz M.A. (Eds). Clinical Gynecologic Endocrinology and Infertility (2005), Lippincott Williams & Wilkins, Philadelphia 779-804
5. Caro J.F., Sinha M.K., Kolaczynski J.W., Zhang P.L., and Considine R.V. Leptin: the tale of an obesity gene. Diabetes 45 (1996) 1455-1462
6. Sepilian V.P., Crochet J.R., and Nagamani M. Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens. Fertil Steril 85 (2006) 1441-1447
7. Erturk E., Kuru N., Savci V., Tuncel E., Ersoy C., and Imamoglu S. Serum leptin levels correlate with obesity parameters but not with hyperinsulinism in women with polycystic ovary syndrome. Fertil Steril 82 (2004) 1364-1368
8. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
9. Kojima M., Hosoda H., Matsuo H., and Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 12 (2001) 118-122
10. Muccioli G., Tschop M., Papotti M., Deghenghi R., Heiman M., and Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 440 (2002) 235-254
11. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., and Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50 (2001) 1714-1719
12. Tschop M., Weyer C., Tataranni A.P., Devanarayan V., Ravussin E., and Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001) 707-709
13. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86 (2001) 5992-5995
14. Oral Contraception. In: Speroff L., and Fritz M.A. (Eds). Clinical Gynecologic Endocrinology and Infertility (2005), Lippincott Williams & Wilkins, Philadelphia 861-942
15. Godsland I.F., Crook D., Simpson R., Proudler T., Felton C., Lees B., et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323 (1990) 1375-1381
16. Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., and Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5 (2000) 124-134 Erratum Eur J Contracept Reprod Health Care 2001;6:63
17. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
18. Ferriman D., and Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21 (1961) 1440-1447
19. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
20. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of the low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
21. Muhn P., Krattenmacher R., Beier S., Elger W., and Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity: pharmacological characterization in animal models. Contraception 51 (1995) 99-110
22. Guido M., Romualdi D., Giuliani M., Suriano R., Selvaggi L., Apa R., et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89 (2004) 2817-2823
23. Ibanez L., and de Zegher F. Ethinyl estradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89 (2004) 1592-1597
24. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (2000) 29-38
25. Taneepanichskul S., and Phupong V. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecol Endocrinol 23 (2007) 347-350
26. Oelkers W., Foidart J.M., Dombrovicz N., Welter A., and Heithecker R. Effects of new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80 (1995) 1816-1821
27. Parsey K.S., and Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61 (2000) 105-111
28. Pehlivanov B., and Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 12 (2007) 30-35
29. Gaspard U., Scheen A., Endrikat J., Buicu C., Lefebvre P., Gerlinger C., et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinyl estradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 67 (2003) 423-429
30. Pagotto U., Gambineri A., Vicennati V., Heiman M.L., Tschöp M., and Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 87 (2002) 5625-5629
31. Schöfl C., Horn R., Schill T., Schlösser H.W., Müller M.J., and Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 4607-4610
32. Panidis D., Farmakiotis D., Koliakos G., Rousso D., Kourtis A., Katsikis I., et al. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum Reprod 20 (2005) 2127-2132
33. Orio Jr. F., Lucidi P., Palomba S., Tauchmanova L., Cascella T., Russo T., et al. Circulating ghrelin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 942-945
34. Wasko R., Komarowska H., Warenik-Szymankiewicz A., and Sowinski J. Elevated ghrelin plasma levels in patients with polycystic ovary syndrome. Horm Metab Res 36 (2004) 170-173
35. Shiiya T., Nakazato M., Mizuta M., Date Y., Mondal M.S., Tanaka M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87 (2002) 240-244
36. Glintborg D., Andersen M., Hagen C., Frystyk J., Hulstrøm V., Flyvbjerg A., et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 155 (2006) 337-345
37. Broglio F., Arvat E., Benso A., Gottero C., Muccioli G., Papotti M., et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 86 (2001) 5083-5086
38. Saad M.F., Bernaba B., Hwu C.M., Jinagouda S., Fahmi S., Kogosov E., et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 87 (2002) 3997-4000
39. Ikezaki A., Hosoda H., Ito K., Iwama S., Miura N., Matsuoka H., et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 51 (2002) 3408-3411
40. Papotti M., Ghe C., Cassoni P., Catapano F., Deghenghi R., Ghigo E., et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 85 (2000) 3803-3807
41. Tena-Sempere M., Barreiro M.L., Gonzalez L.C., Gaytan F., Zhang F.P., Caminos J.E., et al. Novel expression and functional role of ghrelin in rat testis. Endocrinology 143 (2002) 717-725
42. Rosicka M., Krsek M., Matoulek M., Jarkovska Z., Marek J., Justova V., et al. Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptors levels. Physiol Res 52 (2003) 61-66
43. Rouru J., Anttila L., Koskinen P., Penttilä T.A., Irjala K., Huupponen R., et al. Serum leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 1697-1700
44. Mantzoros C.S., Dunaif A., and Flier J.S. Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 1687-1691
45. Krotkiewski M., Landin K., Dahlgren E., Janson P.O., and Holm G. Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS. Gynecol Obstet Invest 55 (2003) 88-95
46. Sagsoz N., Akcay F., and Bayram M. Effects of oral contraceptives with low-dose estrogen and desogestrel on leptin concentrations. J Reprod Med 47 (2002) 545-548
47. Rechberger T., Baranowski W., Postawski K., Jakimiuk A.J., Tomaszewski J., Kulik-Rechberger B., et al. Serum leptin concentrations in women taking oral contraceptives. Euro J Obstet Gynecol Reprod Biol 83 (1999) 105-108
48. Morin-Papunen L., Vauhkonen I., Koivunen R., Ruokonen A., Martikainen H., and Tapanainen J.S. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 88 (2003) 148-156
49. Sahin I., Serter R., Karakurt F., Demirbas B., Guler S., Culha C., et al. Leptin levels increase during flutamide therapy in women with polycystic ovary syndrome. Horm Res 60 (2003) 232-236
50. Gambineri A., Pagotto U., Tschop M., Vicennati V., Manicardi E., Carcello A., et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest 26 (2003) 629-634
51. Romero-Corral A., Sierra-Johnson J., Lopez-Jimenez F., Thomas R.J., Singh P., Hoffmann M., et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat Clin Pract Cardiovasc Med 22 (2008)
52. Tesauro M., Schinzari F., Iantorno M., Rizza S., Melina D., Lauro D., et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 112 (2005) 2986-2992
53. Isgaard J., Barlind A., and Johansson I. Cardiovascular effects of ghrelin and growth hormone secretagogues. Cardiovasc Hematol Disord Drug Targets 8 (2008) 133-137
54. Pöykkö S.M., Kellokoski E., Hörkkö S., Kauma H., Kesäniemi Y.A., and Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52 (2003) 2546-2553